Clinical experience with perindopril in African-American hypertensive patients: A large United States community trial

Jay N. Cohn, Stevo Julius, Joel Neutel, Michael Weber, Prasad Turlapaty, Yannan Shen, Victor Dong, Alicia Batchelor, Weinong Guo, Hjalmar Lagast

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: The prevalence of hypertension is greater in African Americans, and management of this condition presents challenges for practicing physicians. Methods: The effectiveness and safety of perindopril was evaluated in hypertensive African-American patients (n = 1412) and hypertensive white patients (n = 7745) who had participated in a large United States community trial. Patients received perindopril 4 mg once daily for 6 weeks. Based on physicians' clinical judgment at week 6, the dose was either maintained or increased to 8 mg for an additional 6 weeks. Results: Reduction of blood pressure (BP) was significant with perindopril monotherapy (4 to 8 mg once daily) in African Americans and whites (P < .001). The magnitude of BP reduction was significantly more in whites (P < .001). Up-titration of perindopril achieved additional BP reduction in both ethnic groups (P < .001). Control of BP (<140/90 mm Hg) in elderly (>65 years of age) and diabetic African-Americans subgroups was achieved in 32.1% and 31.6%, respectively. Perindopril was safe and well tolerated. Conclusions: Perindopril monotherapy is effective and is a viable initial therapeutic option as an antihypertensive agent in African-American individuals with hypertension.

Original languageEnglish (US)
Pages (from-to)134-138
Number of pages5
JournalAmerican Journal of Hypertension
Volume17
Issue number2
DOIs
StatePublished - Feb 2004

Fingerprint

Perindopril
African Americans
Hypertension
Physicians
Antihypertensive Agents
Blood Pressure
Safety

Keywords

  • African Americans
  • Hypertension
  • Perindopril
  • Up-titration

Cite this

Clinical experience with perindopril in African-American hypertensive patients : A large United States community trial. / Cohn, Jay N.; Julius, Stevo; Neutel, Joel; Weber, Michael; Turlapaty, Prasad; Shen, Yannan; Dong, Victor; Batchelor, Alicia; Guo, Weinong; Lagast, Hjalmar.

In: American Journal of Hypertension, Vol. 17, No. 2, 02.2004, p. 134-138.

Research output: Contribution to journalArticle

Cohn, JN, Julius, S, Neutel, J, Weber, M, Turlapaty, P, Shen, Y, Dong, V, Batchelor, A, Guo, W & Lagast, H 2004, 'Clinical experience with perindopril in African-American hypertensive patients: A large United States community trial', American Journal of Hypertension, vol. 17, no. 2, pp. 134-138. https://doi.org/10.1016/j.amjhyper.2003.09.017
Cohn, Jay N. ; Julius, Stevo ; Neutel, Joel ; Weber, Michael ; Turlapaty, Prasad ; Shen, Yannan ; Dong, Victor ; Batchelor, Alicia ; Guo, Weinong ; Lagast, Hjalmar. / Clinical experience with perindopril in African-American hypertensive patients : A large United States community trial. In: American Journal of Hypertension. 2004 ; Vol. 17, No. 2. pp. 134-138.
@article{016991e97b3b4e8dac2f0569207e5b90,
title = "Clinical experience with perindopril in African-American hypertensive patients: A large United States community trial",
abstract = "Background: The prevalence of hypertension is greater in African Americans, and management of this condition presents challenges for practicing physicians. Methods: The effectiveness and safety of perindopril was evaluated in hypertensive African-American patients (n = 1412) and hypertensive white patients (n = 7745) who had participated in a large United States community trial. Patients received perindopril 4 mg once daily for 6 weeks. Based on physicians' clinical judgment at week 6, the dose was either maintained or increased to 8 mg for an additional 6 weeks. Results: Reduction of blood pressure (BP) was significant with perindopril monotherapy (4 to 8 mg once daily) in African Americans and whites (P < .001). The magnitude of BP reduction was significantly more in whites (P < .001). Up-titration of perindopril achieved additional BP reduction in both ethnic groups (P < .001). Control of BP (<140/90 mm Hg) in elderly (>65 years of age) and diabetic African-Americans subgroups was achieved in 32.1{\%} and 31.6{\%}, respectively. Perindopril was safe and well tolerated. Conclusions: Perindopril monotherapy is effective and is a viable initial therapeutic option as an antihypertensive agent in African-American individuals with hypertension.",
keywords = "African Americans, Hypertension, Perindopril, Up-titration",
author = "Cohn, {Jay N.} and Stevo Julius and Joel Neutel and Michael Weber and Prasad Turlapaty and Yannan Shen and Victor Dong and Alicia Batchelor and Weinong Guo and Hjalmar Lagast",
year = "2004",
month = "2",
doi = "10.1016/j.amjhyper.2003.09.017",
language = "English (US)",
volume = "17",
pages = "134--138",
journal = "American Journal of Hypertension",
issn = "0895-7061",
number = "2",

}

TY - JOUR

T1 - Clinical experience with perindopril in African-American hypertensive patients

T2 - A large United States community trial

AU - Cohn, Jay N.

AU - Julius, Stevo

AU - Neutel, Joel

AU - Weber, Michael

AU - Turlapaty, Prasad

AU - Shen, Yannan

AU - Dong, Victor

AU - Batchelor, Alicia

AU - Guo, Weinong

AU - Lagast, Hjalmar

PY - 2004/2

Y1 - 2004/2

N2 - Background: The prevalence of hypertension is greater in African Americans, and management of this condition presents challenges for practicing physicians. Methods: The effectiveness and safety of perindopril was evaluated in hypertensive African-American patients (n = 1412) and hypertensive white patients (n = 7745) who had participated in a large United States community trial. Patients received perindopril 4 mg once daily for 6 weeks. Based on physicians' clinical judgment at week 6, the dose was either maintained or increased to 8 mg for an additional 6 weeks. Results: Reduction of blood pressure (BP) was significant with perindopril monotherapy (4 to 8 mg once daily) in African Americans and whites (P < .001). The magnitude of BP reduction was significantly more in whites (P < .001). Up-titration of perindopril achieved additional BP reduction in both ethnic groups (P < .001). Control of BP (<140/90 mm Hg) in elderly (>65 years of age) and diabetic African-Americans subgroups was achieved in 32.1% and 31.6%, respectively. Perindopril was safe and well tolerated. Conclusions: Perindopril monotherapy is effective and is a viable initial therapeutic option as an antihypertensive agent in African-American individuals with hypertension.

AB - Background: The prevalence of hypertension is greater in African Americans, and management of this condition presents challenges for practicing physicians. Methods: The effectiveness and safety of perindopril was evaluated in hypertensive African-American patients (n = 1412) and hypertensive white patients (n = 7745) who had participated in a large United States community trial. Patients received perindopril 4 mg once daily for 6 weeks. Based on physicians' clinical judgment at week 6, the dose was either maintained or increased to 8 mg for an additional 6 weeks. Results: Reduction of blood pressure (BP) was significant with perindopril monotherapy (4 to 8 mg once daily) in African Americans and whites (P < .001). The magnitude of BP reduction was significantly more in whites (P < .001). Up-titration of perindopril achieved additional BP reduction in both ethnic groups (P < .001). Control of BP (<140/90 mm Hg) in elderly (>65 years of age) and diabetic African-Americans subgroups was achieved in 32.1% and 31.6%, respectively. Perindopril was safe and well tolerated. Conclusions: Perindopril monotherapy is effective and is a viable initial therapeutic option as an antihypertensive agent in African-American individuals with hypertension.

KW - African Americans

KW - Hypertension

KW - Perindopril

KW - Up-titration

UR - http://www.scopus.com/inward/record.url?scp=9144236818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9144236818&partnerID=8YFLogxK

U2 - 10.1016/j.amjhyper.2003.09.017

DO - 10.1016/j.amjhyper.2003.09.017

M3 - Article

C2 - 14751655

AN - SCOPUS:9144236818

VL - 17

SP - 134

EP - 138

JO - American Journal of Hypertension

JF - American Journal of Hypertension

SN - 0895-7061

IS - 2

ER -